Skip to content Skip to footer
Subscribe Now
NEWS

Sandoz Acquires Just-Evotec Biologics EU SAS in Toulouse to Strengthen its In-House Biosimilar Capabilities

Shots: Sandoz agreed to acquire Just-Evotec Biologics EU SAS in Toulouse , including its manufacturing site to expand in-house continuous manufacturing for biosimilars, supporting its strategy to capture a projected ~$300B biosimilars market over the next decade Sandoz will buy 100% of Just-Evotec Biologics SAS and secure a perpetual license for its continuous manufacturing platform…
November 5, 2025

Read more

NEWS

Ipsen Acquires ImCheck Therapeutics, Enhancing its Oncology Leadership and Strengthening its Pipeline

Shots: Ipsen enters into a definitive share purchase agreement with ImCheck Therapeutics to acquire later's all issued and outstanding shares, including lead candidate ICT01, a P-I/II therapy for 1L AML pts ineligible for intensive CT As per the deal, shareholders of ImCheck Therapeutics will receive €350M ($406.62M) in closing purchase price, with additional deferred payments…
October 23, 2025

Read more

NEWS

Ventus Therapeutics Partners with Genentech to Develop Small-Molecule Drugs Using ReSOLVE Platform

Shots: Ventus Therapeutics has entered a multi-year collaboration with Genentech to discover and optimize novel small-molecule drugs for major diseases using its ReSOLVE platform As per the deal, Ventus will utilize its ReSOLVE platform to identify small-molecule leads for multiple targets, while Genentech will be responsible for preclinical, clinical, and commercial development. Ventus will receive…
October 23, 2025

Read more

NEWS

Takeda Partners with Innovent Biologics to Boost Oncology Pipeline with Advanced Solid Tumor Therapies

Shots: Takeda & Innovent Biologics have entered into a global Partnership (Excluding Greater China) to develop & Commercialize IBI363 & IBI343; Takeda also Gains exclusive Option to license global rights for IBI3001 outside of Greater China As per the deal, Takeda will pay Innovent $1.2B upfront, including a $100M equity investment, funded from cash on…
October 23, 2025

Read more

NEWS

BioArctic and Novartis sign agreement for BrainTransporter ~$802M

Shots: BioArctic has entered into an option, collaboration, and license agreement with Novartis to develop a neurodegeneration treatment using BrainTransporter As per the deal, BioArctic receives $30M upfront and could earn up to $772M in milestones plus tiered mid-single-digit royalties if Novartis licenses and commercializes the drug BioArctic will develop a drug candidate using BrainTransporter and a Novartis…
August 26, 2025

Read more

NEWS

AbbVie Acquires Gilgamesh Pharmaceuticals’ Bretisilocin to Expand Psychiatry Pipeline for ~$1.2B

Shots: AbbVie has signed a definitive agreement to acquire Gilgamesh Pharmaceuticals’ Bretisilocin for moderate-to-severe major depressive disorder (MDD), currently in clinical development As per the deal, AbbVie will acquire Gilgamesh’s bretisilocin program for ~$1.2B, including upfront and milestone payments. Gilgamesh will spin off Gilgamesh Pharma Inc. to retain its team and other programs, including blixeprodil…
August 26, 2025

Read more

NEWS

Royalty Pharma Signs Agreement to Acquire Interest in Amgen’s Imdelltra Royalties from BeOne Medicines for ~$950M

Shots: Royalty Pharma has acquired a royalty interest in Amgen’s Imdelltra from BeOne Medicines for ~$950M As per the deal, Royalty Pharma will acquire BeOne’s ~7% royalty on global Imdelltra sales for ~$950M, including $885M upfront and an option for BeOne to sell more for $65M within 12mos. The royalty, including shared sales above $1.5B…
August 26, 2025

Read more

NEWS

AbbVie to Acquire Capstan Therapeutics for ~$2.1B

Shots: AbbVie has entered into a definitive agreement to acquire Capstan Therapeutics, including its P-I CPTX2309 and proprietary tLNP platform for in vivo RNA delivery to treat B-cell-mediated autoimmune diseases As per the deal, Capstan will receive up to $2.1B in cash, pending customary closing conditions and regulatory approvals CPTX2309 is a tLNP delivering mRNA…
July 1, 2025

Read more

Load more